NeuroSearch has issued 185,755 new shares in a directed issuance to the sellers of Carlsson Research AB

Announcement



NeuroSearch has issued 185,755 new shares in a directed issuance to the sellers
of Carlsson Research AB 

NeuroSearch hereby announces that today 185,755 new shares of DKK 20 nominal
value each, corresponding to a total nominal capital increase of DKK 3,715,100,
have been registered with the Danish Commerce and Companies Agency. As
announced on 17 January 2008, the new shares have been issued to the sellers of
Carlsson Research AB at a price of DKK 319.21 each as milestone payment
relating to the start-up of the Phase I study with the drug candidate ACR343. 

Upon registration of the new shares, NeuroSearch A/S' share capital is DKK
308,568,840 (15,428,442 shares of DKK 20 nominal value each). 

The new shares will be subscribed and admitted to trading and official listing
on OMX Nordic Exchange Copenhagen A/S under the ISIN of NeuroSearch's existing
shares (ISIN DK0010224666) on 24 January 2008. 

Pursuant to the share purchase agreement with the sellers of Carlsson Research
AB, the new shares are subject to a lock-up which will expire 30 days from 17
January 2008. 


Asger Aamund 
Chairman of the Board



Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4460 8212 or +45 4017 5103 



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar
disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the
treatment of various CNS diseases - both (Phase I) in collaboration with
Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in
Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio
of preclinical drug candidates and holds equity interests in several biotech
companies.